A double‐blind comparison of levodopa, madopa, and sinemet in Parkinson disease
Identifieur interne : 002C14 ( Main/Exploration ); précédent : 002C13; suivant : 002C15A double‐blind comparison of levodopa, madopa, and sinemet in Parkinson disease
Auteurs : Diamond [États-Unis] ; Charles H. Markham [États-Unis] ; Leo J. Treciokas [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1978-03.
Abstract
A sixteen‐week study examined the effect of Madopa and Sinemet on patients with Parkinson disease suffering nausea or vomiting as side‐effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease. Following a control period on levodopa, 20 patients underwent four consecutive four‐week regimens as follows: (1) double‐blind, in which a randomized half received levodopa and half received Madopa; (2) single‐blind, in which all received Madopa; (3) double‐blind, in which a re‐randomized half received Madopa and half Sinemet; and (4) single‐blind, in which all received Sinemet. Levodopa administration via Sinemet and Madopa was held to a fixed 20% of prior levodopa dosage. Almost all patients showed great reduction in nausea and vomiting with both Madopa and Sinemet. Seventy percent of the patients showed improvement in disability compared to their levodopa baseline levels. Group means showed no difference between the improvement seen on Madopa and that seen on Sinemet. However, examination of individual responses showed that the majority of patients fared distinctly better on either Sinemet or Madopa.
Url:
DOI: 10.1002/ana.410030314
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double‐blind comparison of levodopa, madopa, and sinemet in Parkinson disease</title><author><name sortKey="Diamond" sort="Diamond" uniqKey="Diamond" last="Diamond">Diamond</name></author><author><name sortKey="Markham, Charles H" sort="Markham, Charles H" uniqKey="Markham C" first="Charles H." last="Markham">Charles H. Markham</name></author><author><name sortKey="Treciokas, Leo J" sort="Treciokas, Leo J" uniqKey="Treciokas L" first="Leo J." last="Treciokas">Leo J. Treciokas</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F5A420AC591D1D09DD00D5DC484E0E2D12F46708</idno><date when="1978" year="1978">1978</date><idno type="doi">10.1002/ana.410030314</idno><idno type="url">https://api.istex.fr/document/F5A420AC591D1D09DD00D5DC484E0E2D12F46708/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000647</idno><idno type="wicri:Area/Main/Curation">000564</idno><idno type="wicri:Area/Main/Exploration">002C14</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A double‐blind comparison of levodopa, madopa, and sinemet in Parkinson disease</title><author><name sortKey="Diamond" sort="Diamond" uniqKey="Diamond" last="Diamond">Diamond</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Reed Neurological Research Center, UCLA School of Medicine, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Markham, Charles H" sort="Markham, Charles H" uniqKey="Markham C" first="Charles H." last="Markham">Charles H. Markham</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Reed Neurological Research Center, UCLA School of Medicine, Los Angeles</wicri:cityArea></affiliation></author><author><name sortKey="Treciokas, Leo J" sort="Treciokas, Leo J" uniqKey="Treciokas L" first="Leo J." last="Treciokas">Leo J. Treciokas</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Reed Neurological Research Center, UCLA School of Medicine, Los Angeles</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1978-03">1978-03</date><biblScope unit="volume">3</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="267">267</biblScope><biblScope unit="page" to="272">272</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">F5A420AC591D1D09DD00D5DC484E0E2D12F46708</idno><idno type="DOI">10.1002/ana.410030314</idno><idno type="ArticleID">ANA410030314</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A sixteen‐week study examined the effect of Madopa and Sinemet on patients with Parkinson disease suffering nausea or vomiting as side‐effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease. Following a control period on levodopa, 20 patients underwent four consecutive four‐week regimens as follows: (1) double‐blind, in which a randomized half received levodopa and half received Madopa; (2) single‐blind, in which all received Madopa; (3) double‐blind, in which a re‐randomized half received Madopa and half Sinemet; and (4) single‐blind, in which all received Sinemet. Levodopa administration via Sinemet and Madopa was held to a fixed 20% of prior levodopa dosage. Almost all patients showed great reduction in nausea and vomiting with both Madopa and Sinemet. Seventy percent of the patients showed improvement in disability compared to their levodopa baseline levels. Group means showed no difference between the improvement seen on Madopa and that seen on Sinemet. However, examination of individual responses showed that the majority of patients fared distinctly better on either Sinemet or Madopa.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Diamond" sort="Diamond" uniqKey="Diamond" last="Diamond">Diamond</name></region><name sortKey="Markham, Charles H" sort="Markham, Charles H" uniqKey="Markham C" first="Charles H." last="Markham">Charles H. Markham</name><name sortKey="Treciokas, Leo J" sort="Treciokas, Leo J" uniqKey="Treciokas L" first="Leo J." last="Treciokas">Leo J. Treciokas</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F5A420AC591D1D09DD00D5DC484E0E2D12F46708
|texte= A double‐blind comparison of levodopa, madopa, and sinemet in Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |